A comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis

Shamshiripour, Parisa; Nikoobakht, Mehdi; Mansourinejad, Zahra; Ahmadvand, Davoud; Akbarpour, Mahzad

doi:10.1080/14760584.2022.2027759

Cited by 6 publications

(7 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 61 Shamshiripour et al also meta-analyzed studies of DC-based therapy for gliomas, concluding it was safe with minimal grade III/IV adverse events. 62 Dafni et al in 2021 meta-analyzed cancer vaccines (peptide and cell-based vaccines) in breast and ovarian cancer, looking primarily at ORR and observed a modest response rate. 63 These studies have provided important evidence for potential benefits of therapeutic cancer vaccines in specific cancer types.…”

Section: Discussionmentioning

confidence: 99%

Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis

Tiwari,

Alcover,

Carpenter

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Cell-based therapeutic cancer vaccines use autologous patient-derived tumor cells, allogeneic cancer cell lines or autologous antigen presenting cells to mimic the natural immune process and stimulate an adaptive immune response against tumor antigens. The primary objective of this study is to perform a systematic literature review with an embedded meta-analysis of all published Phase 2 and 3 clinical trials of cell-based cancer vaccines in human subjects. The secondary objective of this study is to review trials demonstrating biological activity of cell-based cancer vaccines that could uncover additional hypotheses, which could be used in the design of future studies. We performed the systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The final review included 36 studies − 16 single-arm studies, and 20 controlled trials. Our systematic review of the existing literature revealed largely negative trials and our meta-analysis did not show evidence of clinical benefit from cell-based cancer-vaccines. However, as we looked beyond the stringent inclusion criteria of our systematic review, we identified significant examples of biological activity of cell-based cancer vaccines that are worth highlighting. In conclusion, the existing literature on cell-based cancer vaccines is highly variable in terms of cancer type, vaccine therapies and the clinical setting with no overall statistically significant clinical benefit, but there are individual successes that represent the promise of this approach. As cell-based vaccine technology continues to evolve, future studies can perhaps fulfill the potential that this exciting field of anti-cancer therapy holds.

show abstract

Section: Discussionmentioning

confidence: 99%

Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis

Tiwari,

Alcover,

Carpenter

et al. 2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…In the current work, we used EVs as delivery vehicles for BBB targeting and performed EV conjugation with folate to improve the BBB trafficking of our previously proposed theranostic vesicle “VEGF-A siDOX-EVs”. Mounting the previous studies, DC-EVs possess unique protein cargo which could insert significant impacts on combating glioma growth by activating the anti-tumor immune responses ( 20 ). Moreover, by using the exosomes derived from mesenchymal stem cells (MSC-EVs), potent regeneration was reported ( 39 ).…”

Section: Discussionmentioning

confidence: 99%

A dynamic study of VEGF-A siDOX-EVs trafficking through the in-vitro insert co-culture blood-brain barrier model by digital holographic microscopy

Shamshiripour,

Rahnama,

Nikoobakht

et al. 2024

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

IntroductionModeling the blood-brain barrier has long been a challenge for pharmacological studies. Up to the present, numerous attempts have been devoted to recapitulating the endothelial barrier in vitro to assess drug delivery vehicles’ efficiency for brain disorders. In the current work, we presented a new approach for analyzing the morphometric parameters of the cells of an insert co-culture blood-brain barrier model using rat brain astrocytes, rat brain microvascular endothelial cells, and rat brain pericytes. This analytical approach could aid in getting further information on drug trafficking through the blood-brain barrier and its impact on the brain indirectly.MethodsIn the current work, we cultured rat brain astrocytes, rat brain microvascular endothelial cells, and rat brain pericytes and then used an insert well to culture the cells in contact with each other to model the blood-brain barrier. Then, the morphometric parameters of the porous membrane of the insert well, as well as each cell type were imaged by digital holographic microscopy before and after cell seeding. At last, we performed folate conjugation on the surface of the EVs we have previously tested for glioma therapy in our previous work called VEGF-A siDOX-EVs and checked how the trafficking of EVs improves after folate conjugation as a clathrin-mediated delivery setup. the trafficking and passage of EVs were assessed by flow cytometry and morphometric analysis of the digital holographic microscopy holograms.ResultsOur results indicated that EVs successfully entered through the proposed endothelial barrier assessed by flow cytometry analysis and furthermore, folate conjugation significantly improved EV passage through the blood-brain barrier. Moreover, our results indicated that the VEGF-A siDOX-EVs insert cytotoxic impact on the cells of the bottom of the culture plate.Conclusionfolate-conjugation on the surface of EVs improves their trafficking through the blood-brain barrier and by using digital holographic microscopy analysis, we could directly assess the morphometric changes of the blood-brain barrier cells for pharmacological purposes as an easy, label-free, and real-time analysis.

show abstract

“…The results of this study challenged the results of previous meta-analysis and led to rise more uncertainties in terms of DC-based vaccines. However, a current metaanalysis showed efficacy of DC therapy for malignant gliomas and immune responses via induction of CD8 + T cells, while they also reported fatigue as most common adverse effects of this treatment method [38]. Considering that these studies focused on only DC-based therapies, these vaccines were not compared to other vaccines before.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis

Amanzadeh Jajin,

Oraee Yazdani,

Zali

et al. 2024

Oncol.Rev.

View full text Add to dashboard Cite

Background:Malignant gliomas are known with poor prognosis and low rate of survival among brain tumors. Resection surgery is followed by chemotherapy and radiotherapy in treatment of gliomas which is known as the conventional treatment. However, this treatment method results in low survival rate. Vaccination has been suggested as a type of immunotherapy to increase survival rate of glioma patients. Different types of vaccines have been developed that are mainly classified in two groups including peptide vaccines and cell-based vaccines. However, there are still conflicts about which type of vaccines is more efficient for malignant glioma treatment.Methods:Phase Ⅰ/Ⅱ clinical trials which compared the efficacy and safety of various vaccines with conventional treatments were searched in databases through November 2022. Overall survival (OS) rate, progression free survival (PFS), and OS duration were used for calculation of pooled risk ratio (RR). In addition, fatigue, headache, nausea, diarrhea, and flu-like syndrome were used for evaluating the safety of vaccines therapy in glioma patients.Results:A total of twelve articles were included in the present meta-analysis. Comparison of OS rate between vaccinated groups and control groups who underwent only conventional treatments showed a significant increase in OS rate in vaccinated patients (I2 = 0%, RR = 11.17, 95% CI: 2.460–50.225). PFS rate was better in vaccinated glioma patients (I2 = 83%, RR = 2.87, 95% CI: 1.63–5.03). Assessment of safety demonstrated that skin reaction (I2 = 0.0%, RR = 3.654; 95% CI: 1.711–7.801, p-value = 0.0058) and flu-like syndrome were significantly more frequent adverse effects win vaccinated groups compared to the control group. Subgroup analysis also showed that vaccination leads to better OS duration in recurrent gliomas than primary gliomas, and in LGG than HGG (p-value = 0). On the other hand, personalized vaccines showed better OS duration than non-personalized vaccines (p-value = 0).Conclusion:Vaccination is a type of immunotherapy which shows promising efficacy in treatment of malignant glioma patients in terms of OS, PFS and duration of survival. In addition, AFTV, peptide, and dendritic cell-based vaccines are among the most efficient vaccines for gliomas. Personalized vaccines also showed considerable efficacy for glioma treatments.

show abstract

A comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis

Cited by 6 publications

References 107 publications

Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis

Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis

A dynamic study of VEGF-A siDOX-EVs trafficking through the in-vitro insert co-culture blood-brain barrier model by digital holographic microscopy

Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About